Review



rabbit polyclonal glut1 antibody 355 a 15  (Cell Marque)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Cell Marque rabbit polyclonal glut1 antibody 355 a 15
    Comparison of <t>GLUT1</t> immunostaining results with previous GLUT1 studies. An „X“ indicates the fraction of GLUT1 positive cancer cells in the present study, dots indicate the reported frequencies from the literature for comparison: red dots mark studies with ≤10 analyzed tumors, yellow dots mark studies with ≥11 ≤ 25 analyzed tumors and green dots mark studies with > 25 analyzed tumors. All studies are listed in supplementary table 1. Locations of specific tumors types include seminoma of the testis, soft tissue rhabdoid tu-mors, teratomas of the testis, and typical as well as typical and atypical neuroendocrine of the lungs
    Rabbit Polyclonal Glut1 Antibody 355 A 15, supplied by Cell Marque, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit polyclonal glut1 antibody 355 a 15/product/Cell Marque
    Average 86 stars, based on 1 article reviews
    rabbit polyclonal glut1 antibody 355 a 15 - by Bioz Stars, 2026-06
    86/100 stars

    Images

    1) Product Images from "Glucose-transporter 1 (GLUT1) as a prognostic biomarker: evidence from 14,966 human tumors across 134 cancer types"

    Article Title: Glucose-transporter 1 (GLUT1) as a prognostic biomarker: evidence from 14,966 human tumors across 134 cancer types

    Journal: BMC Cancer

    doi: 10.1186/s12885-025-15527-5

    Comparison of GLUT1 immunostaining results with previous GLUT1 studies. An „X“ indicates the fraction of GLUT1 positive cancer cells in the present study, dots indicate the reported frequencies from the literature for comparison: red dots mark studies with ≤10 analyzed tumors, yellow dots mark studies with ≥11 ≤ 25 analyzed tumors and green dots mark studies with > 25 analyzed tumors. All studies are listed in supplementary table 1. Locations of specific tumors types include seminoma of the testis, soft tissue rhabdoid tu-mors, teratomas of the testis, and typical as well as typical and atypical neuroendocrine of the lungs
    Figure Legend Snippet: Comparison of GLUT1 immunostaining results with previous GLUT1 studies. An „X“ indicates the fraction of GLUT1 positive cancer cells in the present study, dots indicate the reported frequencies from the literature for comparison: red dots mark studies with ≤10 analyzed tumors, yellow dots mark studies with ≥11 ≤ 25 analyzed tumors and green dots mark studies with > 25 analyzed tumors. All studies are listed in supplementary table 1. Locations of specific tumors types include seminoma of the testis, soft tissue rhabdoid tu-mors, teratomas of the testis, and typical as well as typical and atypical neuroendocrine of the lungs

    Techniques Used: Comparison, Immunostaining

    GLUT1 immunostaining in normal tissue. GLUT1 staining was typically membranous but also cytoplasmic. The panels show strong GLUT1 staining in amnion and chorion cells of the placenta ( A ), predominantly membranous staining in cyto- and syncytiotrophoblasts of a mature placenta ( B ), lack of GLUT1 staining of cerebral cells with a strong staining of small vessel cells in the grey cerebrum ( C ), moderate GLUT1 staining of suprabasal cell layers of the anal skin ( D ), focal weak GLUT1 staining in the surface epithelium of the gallbladder ( E ), weak to moderate GLUT1 staining of few collecting ducts in the renal cortex ( F ), weak GLUT1 staining in basal cells of the prostate ( G ), and lack of GLUT1 staining in sinusoidal cells with strong staining of erythrocytes in the liver ( H )
    Figure Legend Snippet: GLUT1 immunostaining in normal tissue. GLUT1 staining was typically membranous but also cytoplasmic. The panels show strong GLUT1 staining in amnion and chorion cells of the placenta ( A ), predominantly membranous staining in cyto- and syncytiotrophoblasts of a mature placenta ( B ), lack of GLUT1 staining of cerebral cells with a strong staining of small vessel cells in the grey cerebrum ( C ), moderate GLUT1 staining of suprabasal cell layers of the anal skin ( D ), focal weak GLUT1 staining in the surface epithelium of the gallbladder ( E ), weak to moderate GLUT1 staining of few collecting ducts in the renal cortex ( F ), weak GLUT1 staining in basal cells of the prostate ( G ), and lack of GLUT1 staining in sinusoidal cells with strong staining of erythrocytes in the liver ( H )

    Techniques Used: Immunostaining, Staining

    GLUT1 immunostaining in cancer. Strong GLUT1 immunostaining in clear cell renal cell carcinoma ( A ), urothelial carcinoma ( B ), colorectal carcinoma ( C ), serous high-grade ovarian carcinoma ( D ), squamous cell carcinoma of the vulva ( E ), endometrioid endometrial carcinoma ( F ), enbryonel carcinoma of the testis ( G ), and absence of GLUT1 immunostaining in hepatocellular carcinoma ( H )
    Figure Legend Snippet: GLUT1 immunostaining in cancer. Strong GLUT1 immunostaining in clear cell renal cell carcinoma ( A ), urothelial carcinoma ( B ), colorectal carcinoma ( C ), serous high-grade ovarian carcinoma ( D ), squamous cell carcinoma of the vulva ( E ), endometrioid endometrial carcinoma ( F ), enbryonel carcinoma of the testis ( G ), and absence of GLUT1 immunostaining in hepatocellular carcinoma ( H )

    Techniques Used: Immunostaining

    Ranking order of GLUT1 immunostaining in tumors. Both the percentage of positive cases (blue dots) and the percentage of strongly positive cases (orange dots) are shown
    Figure Legend Snippet: Ranking order of GLUT1 immunostaining in tumors. Both the percentage of positive cases (blue dots) and the percentage of strongly positive cases (orange dots) are shown

    Techniques Used: Immunostaining

    GLUT1 immunostaining and prognosis in ( A - D ) clear cell renal cell cancer and in ( E - H ) papillary renal cell cancer. A , B ), E ), and F ) show overall survival, C ), D ), G ) and H ) show recurrence free survival. For B ), D ), F and H ), tumors were grouped in GLUT1 “low”, including negative, weak and moderate staining, and GLUT1 “high” (strong) staining
    Figure Legend Snippet: GLUT1 immunostaining and prognosis in ( A - D ) clear cell renal cell cancer and in ( E - H ) papillary renal cell cancer. A , B ), E ), and F ) show overall survival, C ), D ), G ) and H ) show recurrence free survival. For B ), D ), F and H ), tumors were grouped in GLUT1 “low”, including negative, weak and moderate staining, and GLUT1 “high” (strong) staining

    Techniques Used: Immunostaining, Staining



    Similar Products

    rabbit polyclonal glut1 antibody 355 a 15  (Cell Marque)
    86
    Cell Marque rabbit polyclonal glut1 antibody 355 a 15
    Comparison of <t>GLUT1</t> immunostaining results with previous GLUT1 studies. An „X“ indicates the fraction of GLUT1 positive cancer cells in the present study, dots indicate the reported frequencies from the literature for comparison: red dots mark studies with ≤10 analyzed tumors, yellow dots mark studies with ≥11 ≤ 25 analyzed tumors and green dots mark studies with > 25 analyzed tumors. All studies are listed in supplementary table 1. Locations of specific tumors types include seminoma of the testis, soft tissue rhabdoid tu-mors, teratomas of the testis, and typical as well as typical and atypical neuroendocrine of the lungs
    Rabbit Polyclonal Glut1 Antibody 355 A 15, supplied by Cell Marque, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit polyclonal glut1 antibody 355 a 15/product/Cell Marque
    Average 86 stars, based on 1 article reviews
    rabbit polyclonal glut1 antibody 355 a 15 - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Comparison of GLUT1 immunostaining results with previous GLUT1 studies. An „X“ indicates the fraction of GLUT1 positive cancer cells in the present study, dots indicate the reported frequencies from the literature for comparison: red dots mark studies with ≤10 analyzed tumors, yellow dots mark studies with ≥11 ≤ 25 analyzed tumors and green dots mark studies with > 25 analyzed tumors. All studies are listed in supplementary table 1. Locations of specific tumors types include seminoma of the testis, soft tissue rhabdoid tu-mors, teratomas of the testis, and typical as well as typical and atypical neuroendocrine of the lungs

    Journal: BMC Cancer

    Article Title: Glucose-transporter 1 (GLUT1) as a prognostic biomarker: evidence from 14,966 human tumors across 134 cancer types

    doi: 10.1186/s12885-025-15527-5

    Figure Lengend Snippet: Comparison of GLUT1 immunostaining results with previous GLUT1 studies. An „X“ indicates the fraction of GLUT1 positive cancer cells in the present study, dots indicate the reported frequencies from the literature for comparison: red dots mark studies with ≤10 analyzed tumors, yellow dots mark studies with ≥11 ≤ 25 analyzed tumors and green dots mark studies with > 25 analyzed tumors. All studies are listed in supplementary table 1. Locations of specific tumors types include seminoma of the testis, soft tissue rhabdoid tu-mors, teratomas of the testis, and typical as well as typical and atypical neuroendocrine of the lungs

    Article Snippet: For the purpose of antibody validation, the normal tissue TMA was also analyzed by the rabbit polyclonal GLUT1 antibody 355 A-15 (Cell Marque, Rocklin, CA, pH 6.0, 1:200) on a DAKO autostainer Link48 according to a protocol suggested by Agilent DAKO.

    Techniques: Comparison, Immunostaining

    GLUT1 immunostaining in normal tissue. GLUT1 staining was typically membranous but also cytoplasmic. The panels show strong GLUT1 staining in amnion and chorion cells of the placenta ( A ), predominantly membranous staining in cyto- and syncytiotrophoblasts of a mature placenta ( B ), lack of GLUT1 staining of cerebral cells with a strong staining of small vessel cells in the grey cerebrum ( C ), moderate GLUT1 staining of suprabasal cell layers of the anal skin ( D ), focal weak GLUT1 staining in the surface epithelium of the gallbladder ( E ), weak to moderate GLUT1 staining of few collecting ducts in the renal cortex ( F ), weak GLUT1 staining in basal cells of the prostate ( G ), and lack of GLUT1 staining in sinusoidal cells with strong staining of erythrocytes in the liver ( H )

    Journal: BMC Cancer

    Article Title: Glucose-transporter 1 (GLUT1) as a prognostic biomarker: evidence from 14,966 human tumors across 134 cancer types

    doi: 10.1186/s12885-025-15527-5

    Figure Lengend Snippet: GLUT1 immunostaining in normal tissue. GLUT1 staining was typically membranous but also cytoplasmic. The panels show strong GLUT1 staining in amnion and chorion cells of the placenta ( A ), predominantly membranous staining in cyto- and syncytiotrophoblasts of a mature placenta ( B ), lack of GLUT1 staining of cerebral cells with a strong staining of small vessel cells in the grey cerebrum ( C ), moderate GLUT1 staining of suprabasal cell layers of the anal skin ( D ), focal weak GLUT1 staining in the surface epithelium of the gallbladder ( E ), weak to moderate GLUT1 staining of few collecting ducts in the renal cortex ( F ), weak GLUT1 staining in basal cells of the prostate ( G ), and lack of GLUT1 staining in sinusoidal cells with strong staining of erythrocytes in the liver ( H )

    Article Snippet: For the purpose of antibody validation, the normal tissue TMA was also analyzed by the rabbit polyclonal GLUT1 antibody 355 A-15 (Cell Marque, Rocklin, CA, pH 6.0, 1:200) on a DAKO autostainer Link48 according to a protocol suggested by Agilent DAKO.

    Techniques: Immunostaining, Staining

    GLUT1 immunostaining in cancer. Strong GLUT1 immunostaining in clear cell renal cell carcinoma ( A ), urothelial carcinoma ( B ), colorectal carcinoma ( C ), serous high-grade ovarian carcinoma ( D ), squamous cell carcinoma of the vulva ( E ), endometrioid endometrial carcinoma ( F ), enbryonel carcinoma of the testis ( G ), and absence of GLUT1 immunostaining in hepatocellular carcinoma ( H )

    Journal: BMC Cancer

    Article Title: Glucose-transporter 1 (GLUT1) as a prognostic biomarker: evidence from 14,966 human tumors across 134 cancer types

    doi: 10.1186/s12885-025-15527-5

    Figure Lengend Snippet: GLUT1 immunostaining in cancer. Strong GLUT1 immunostaining in clear cell renal cell carcinoma ( A ), urothelial carcinoma ( B ), colorectal carcinoma ( C ), serous high-grade ovarian carcinoma ( D ), squamous cell carcinoma of the vulva ( E ), endometrioid endometrial carcinoma ( F ), enbryonel carcinoma of the testis ( G ), and absence of GLUT1 immunostaining in hepatocellular carcinoma ( H )

    Article Snippet: For the purpose of antibody validation, the normal tissue TMA was also analyzed by the rabbit polyclonal GLUT1 antibody 355 A-15 (Cell Marque, Rocklin, CA, pH 6.0, 1:200) on a DAKO autostainer Link48 according to a protocol suggested by Agilent DAKO.

    Techniques: Immunostaining

    Ranking order of GLUT1 immunostaining in tumors. Both the percentage of positive cases (blue dots) and the percentage of strongly positive cases (orange dots) are shown

    Journal: BMC Cancer

    Article Title: Glucose-transporter 1 (GLUT1) as a prognostic biomarker: evidence from 14,966 human tumors across 134 cancer types

    doi: 10.1186/s12885-025-15527-5

    Figure Lengend Snippet: Ranking order of GLUT1 immunostaining in tumors. Both the percentage of positive cases (blue dots) and the percentage of strongly positive cases (orange dots) are shown

    Article Snippet: For the purpose of antibody validation, the normal tissue TMA was also analyzed by the rabbit polyclonal GLUT1 antibody 355 A-15 (Cell Marque, Rocklin, CA, pH 6.0, 1:200) on a DAKO autostainer Link48 according to a protocol suggested by Agilent DAKO.

    Techniques: Immunostaining

    GLUT1 immunostaining and prognosis in ( A - D ) clear cell renal cell cancer and in ( E - H ) papillary renal cell cancer. A , B ), E ), and F ) show overall survival, C ), D ), G ) and H ) show recurrence free survival. For B ), D ), F and H ), tumors were grouped in GLUT1 “low”, including negative, weak and moderate staining, and GLUT1 “high” (strong) staining

    Journal: BMC Cancer

    Article Title: Glucose-transporter 1 (GLUT1) as a prognostic biomarker: evidence from 14,966 human tumors across 134 cancer types

    doi: 10.1186/s12885-025-15527-5

    Figure Lengend Snippet: GLUT1 immunostaining and prognosis in ( A - D ) clear cell renal cell cancer and in ( E - H ) papillary renal cell cancer. A , B ), E ), and F ) show overall survival, C ), D ), G ) and H ) show recurrence free survival. For B ), D ), F and H ), tumors were grouped in GLUT1 “low”, including negative, weak and moderate staining, and GLUT1 “high” (strong) staining

    Article Snippet: For the purpose of antibody validation, the normal tissue TMA was also analyzed by the rabbit polyclonal GLUT1 antibody 355 A-15 (Cell Marque, Rocklin, CA, pH 6.0, 1:200) on a DAKO autostainer Link48 according to a protocol suggested by Agilent DAKO.

    Techniques: Immunostaining, Staining